Results 141 to 150 of about 18,181 (226)

Impact of Regional Healthcare Policy Interventions on Biosimilar Use: A 10-year Evaluation of TNFα Inhibitors Utilization in Italy. [PDF]

open access: yesPharmaceut Med
Vitturi G   +40 more
europepmc   +1 more source

Impact of Nonmedical Adalimumab Switches in a Rheumatology Patient Population. [PDF]

open access: yesJ Pharm Technol
DelPrete S   +6 more
europepmc   +1 more source

Average Sales Price Erosion of Oncology Biologic Agents Following Biosimilar Entry Into The US Market

open access: yes
Background: Biologic therapies are central in cancer management, but the high acquisition costs limit patient access. Biosimilars, which are equivalent in quality and safety to a reference biologic, are a cost-efficient alternative.
Beddor, Ansam Nail
core   +1 more source

Biosimilar Rituximab in ANCA-Associated Vasculitis Compared to the Originator: A Multicenter Cohort Study. [PDF]

open access: yesACR Open Rheumatol
Mendel A   +14 more
europepmc   +1 more source

Osteoporosis treatment with biosimilars in Malaysia and Thailand: a budget impact analysis. [PDF]

open access: yesArch Osteoporos
Siachalinga L   +7 more
europepmc   +1 more source

Biosimilar use in medical oncology in Ireland: a missed opportunity to mitigate financial toxicity? [PDF]

open access: yesInt J Clin Pharm
Burton E   +7 more
europepmc   +1 more source

Biosimilars in pemphigus vulgaris

open access: yesIndian Journal of Dermatology, 2014
Sharmila Patil   +3 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy